FIG 4.

(A to F) Human sera binding to gB, competition with neutralizing anti-gB MAbs, and statistical analysis of these data was set up in the same manner as described for gD in Fig. 2. For sera from individuals with no recurrent disease, only selected samples from panel B (arrows) were graphed in panel E. Anti-gB MAb competition data for all of the nonrecurrent samples is provided in Table 2. Samples Z1 and Z7, which did not bind gB in panel B, were not tested for MAb competition in panel E. Those with recurrent infections produced Abs that exhibited greater gB binding and anti-gB MAb competition; blocking of all three anti-gB epitopes tested was statistically different between recurrent and nonrecurrent individuals.